Paris
NASH Meeting
July 11 & 12, 2019
Institut Pasteur
5th edition

Organized by

Arun Sanyal
Virginia Commonwealth University School of Medicine,
Richmond, Virginia, USA

Lawrence Serfaty
Hôpital Hautepierre
Hôpitaux Universitaires de Strasbourg, France

Scientific committee

Quentin Anstee
Pierre Bedossa
Laurent Castera
Jean-François Dufour
Scott Friedman
Fabio Marra
Philippe Mathurin
Veronica Miller
Frank Tacke
Michael Trauner

With the partnership of

[Logos of AFEF, Société Francophone diabète, and THE FORUM]
THURSDAY, JULY 11, 2019

08:00 - 08:30 am  CONFERENCE OPENING
08:30 - 08:35 am  Welcome remarks - Lawrence Serfaty (France)
08:35 - 08:45 am  Inauguration Address - Director Institut Pasteur

08:45 - 10:00 am  SESSION 1 • PUBLIC HEALTH AND POLICY
Chairs: Patrick Marcellin (France) and Michael Trauner (Austria)

08:45 - 09:00 am  Patient perspectives on NASH and NAFLD.
Marko Korenjac (Belgium)

09:00 - 09:15 am  European perspectives on NASH - experience from the Constances cohort.
Lawrence Serfaty (France)

09:15 - 09:30 am  The metrics of the value of NASH interventions for patients and payers.
The CoreNASH project update.
Elizabeth Clearfield (USA)

09:30 - 10:00 am  Discussion

10:00 - 10:30 am  COFFEE BREAK AND POSTERS

10:30 - 12:00 am  SESSION 2 • MODIFIABLE DRIVERS OF DISEASE PROGRESSION
Chairs: Fabio Marra (Italy) and Lawrence Serfaty (France)

10:30 - 10:45 am  Can novel genetic markers be leveraged for therapeutics?
Arun Sanyal (USA)

10:45 - 11:00 am  Addiction behavior, depression and other behavioral barriers to successful lifestyle intervention.
Gerard Moeller (USA)

11:00 - 11:15 am  Is alcohol a modulator of disease progression in NASH?
Phillippe Mathurin (France)

11:15 - 11:30 am  Socio-economic and family-based risk factors as drivers of disease severity and outcomes of lifestyle interventions.
Mary Rinella (USA)

11:30 - 12:00 pm  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair(s)</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 12:30 pm</td>
<td><strong>STATE OF THE ART LECTURE</strong></td>
<td>Chair: Arun Sanyal (USA)</td>
<td>The role of the adipocyte in the genesis of NAFLD and NASH Philipp Scherer (USA)</td>
</tr>
<tr>
<td>12:30 - 02:00 pm</td>
<td><strong>LUNCH BREAK</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02:00 - 03:30 pm</td>
<td><strong>SESSION 3 • CLINICAL ASPECTS OF NAFLD</strong></td>
<td>Chairs: Philippe Mathurin (France) and Lawrence Serfaty (France)</td>
<td><img src="speakers.png" alt="Session 3 Speakers" /></td>
</tr>
<tr>
<td>02:00 - 02:20 pm</td>
<td>Controversy: is NAFLD a driver or simple marker of cardiovascular risk?</td>
<td>Franck Boccara (France) vs Fabio Marra (Italy)</td>
<td></td>
</tr>
<tr>
<td>02:20 - 02:35 pm</td>
<td>Is the WHO definition of cirrhosis still relevant in the age of NASH—lessons learned about the evolution of advanced fibrosis in NASH?</td>
<td>Pierre Bedossa (France)</td>
<td></td>
</tr>
<tr>
<td>02:35 - 02:50 pm</td>
<td>Implications of NASH as the etiology of cirrhosis in the context of liver transplantation.</td>
<td>Mohammad Shadab Siddiqui (USA)</td>
<td></td>
</tr>
<tr>
<td>02:50 - 03:05 pm</td>
<td>Familial NAFLD and the risk of fibrosis.</td>
<td>Cyrielle Caussy (France)</td>
<td></td>
</tr>
<tr>
<td>03:05 - 03:30 pm</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>03:30 - 04:00 pm</td>
<td><strong>COFFEE BREAK AND POSTERS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>04:00 - 05:30 pm</td>
<td><strong>SESSION 4 • TECHNOLOGIC INNOVATIONS IN NASH</strong></td>
<td>Chairs: Laurent Castera (France) and Frank Tacke (Germany)</td>
<td><img src="speakers.png" alt="Session 4 Speakers" /></td>
</tr>
<tr>
<td>04:00 - 04:15 pm</td>
<td>Microparticles in disease progression in NASH and their potential utility as diagnostic and predictive biomarkers.</td>
<td>Pierre-Emmanuel Rautou (France)</td>
<td></td>
</tr>
<tr>
<td>04:15 - 04:30 pm</td>
<td>The ability to predict histological response from MR parameters—lessons learned from phase 2 trials.</td>
<td>Michael Middleton (USA)</td>
<td></td>
</tr>
<tr>
<td>04:30 - 04:45 pm</td>
<td>Using technology for care delivery and improving outcomes.</td>
<td>Giulio Marchesini (Italy)</td>
<td></td>
</tr>
<tr>
<td>04:45 - 05:00 pm</td>
<td>Liver tissue engineering: where are we now?</td>
<td>Massimo Pinzani (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>05:00 - 05:30 pm</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>05:30 - 05:45 pm</td>
<td><strong>POSTER AWARD</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
FRIDAY, JULY 12, 2019

07:45 - 08:00 am  WELCOME DESK OPENING

08:00 - 09:30 am  SESSION 5 • DIAGNOSTICS
Chairs: Pierre Bedossa (France) and Arun Sanyal (USA)

08:00 - 08:15 am  How to evaluate the patient with suspected NASH in clinic using currently available tools?
Jean-François Dufour (Switzerland)

08:15 - 08:30 am  A deep-dive into elastography: does methodology matter?
Laurent Castera (France)

08:30 - 08:45 am  Use of proteomics in the assessment of disease activity and stage in NASH.
Yi Luo (USA)

08:45 - 09:00 am  How to improve screening for clinical trials and treatment indication?
Jérôme Boursier (France)

09:00 - 09:30 am  Discussion

09:30 - 10:00 am  COFFEE BREAK

10:00 - 11:30 am  SESSION 6 • ADVANCES IN NASH PHARMACOLOGY
Chairs: Jean-François Dufour (Switzerland) and Arun Sanyal (USA)

10:00 - 10:15 am  Potential use of glucose-lowering drugs (GLP-1 and SGLT2 inhibitors) in NASH.
Michael Roden (Germany)

10:15 - 10:30 am  PPAR biology beyond thiazolidinediones and novel applications for NASH.
Bart Staels (France)

10:30 - 10:45 am  Mitochondrial uncoupling as a target for NASH therapeutics.
Gerald Shulman (USA)

10:45 - 11:00 am  Similarities and differences between classical FXR agonists versus non-steroidal agents.
Michael Trauner (Austria)

11:00 - 11:30 am  Discussion

11:30 - 12:00 pm  SPECIAL LECTURE: PURSUING THE HOLY GRAIL OF PRECISION MEDICINE FOR NASH.
Chair: Arun Sanyal (USA)
12:00 - 02:00 pm  LUNCH BREAKOUT SESSION

GROUP 1: Review of recent clinical trials of NASH.
Raluca Pais (France) and Mary Rinella (USA)

GROUP 2: Progress in development of combination therapeutics.
Frank Tacke (Germany) and Michael Trauner (Austria)

GROUP 3: Managing Cardiometabolic disease and risk in NAFLD.
Fabio Marra (Italy) and Michael Roden (Germany)

GROUP 4: Best approach for diagnosis and triage of NASH in the diabetes clinic.
Bertrand Cariou (France) and Laurent Castera (France)

02:00 - 02:30 pm  SESSION 7 • REGULATORY UPDATE
Chair: Lawrence Serfaty (France)

Veronica Miller (USA)

02:30 - 04:00 pm  SESSION 8 • INDUSTRY SPONSORED SESSION
Chairs: Arun Sanyal (USA) and Lawrence Serfaty (France)

02:30 - 02:40 pm  GILEAD SCIENCES SESSION
Kathryn Kersey

02:40 - 02:50 pm  INTERCEPT PHARMA SESSION
Aldo Trylesinski

02:50 - 03:00 pm  PFIZER SESSION
Fady Ntanios

03:00 - 03:10 pm  ALLERGAN SESSION
Eduardo Bruno Martins

03:10 - 03:20 pm  GENFIT SESSION
Suneil Hosmane

03:20 - 03:30 pm  NOVARTIS SESSION
Clifford Brass

03:30 - 03:40 pm  MSD SESSION
Eirum Chaudhri

03:40 - 04:00 pm  Discussion

04:00 pm  Concluding remarks
<table>
<thead>
<tr>
<th>FACULTY 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>BEDOSSA Pierre</td>
</tr>
<tr>
<td>BOCCARA Franck</td>
</tr>
<tr>
<td>BOURSIER Jérôme</td>
</tr>
<tr>
<td>CARIOU Bertrand</td>
</tr>
<tr>
<td>CASTERA Laurent</td>
</tr>
<tr>
<td>CAUSSY Cyrielle</td>
</tr>
<tr>
<td>CLEARFIELD Elizabeth</td>
</tr>
<tr>
<td>DUFOUR Jean-François</td>
</tr>
<tr>
<td>LUO Yi</td>
</tr>
<tr>
<td>MARCELLIN Patrick</td>
</tr>
<tr>
<td>MARCHESINI Giulio</td>
</tr>
<tr>
<td>MARRA Fabio</td>
</tr>
<tr>
<td>MATHURIN Philippe</td>
</tr>
<tr>
<td>MIDDLETON Michael</td>
</tr>
<tr>
<td>MILLER Veronica</td>
</tr>
<tr>
<td>MOELLER Gerard</td>
</tr>
<tr>
<td>PAIS Raluca</td>
</tr>
<tr>
<td>PINZANI Massimo</td>
</tr>
<tr>
<td>RAUTOU Pierre-Emmanuel</td>
</tr>
<tr>
<td>RINELLA Mary</td>
</tr>
<tr>
<td>RODEN Michael</td>
</tr>
<tr>
<td>SANYAL Arun</td>
</tr>
<tr>
<td>SCHERER Philipp</td>
</tr>
<tr>
<td>SERFATY Lawrence</td>
</tr>
<tr>
<td>SHULMAN Gerald</td>
</tr>
<tr>
<td>SIDIQUI Mohammad Shadab</td>
</tr>
<tr>
<td>STAELS Bart</td>
</tr>
<tr>
<td>TACKE Frank</td>
</tr>
<tr>
<td>TRAUNER Michael</td>
</tr>
</tbody>
</table>
July 11 & 12, 2019, Paris

INSTITUT PASTEUR
28 Rue du Docteur Roux
75015 PARIS • FRANCE

Congress Secretariat
TAMING HEALTHCARE
58, Bd de la République
92100 Boulogne-Billancourt
+33 1 84 20 32 30

Contact:
contact@paris-nash.org

www.paris-nash.org